Pharma wants more balanced payment system in Europe; China's pharma industry records steady 2013 growth;

@FiercePharma: AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says. More | Follow @FiercePharma

@TracyStaton: With new study, Pfizer closes in on $1B-plus sales boost for #Prevnar vaccine. More | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. Article | Follow @EricPFierce

@CarlyHFierce: Vivus beats the street on licensing payments, but investors aren't fooled. Story | Follow @CarlyHFierce

> The pharma industry has called on the European Medicines Agency (EMA) to reexamine how it handles pharmacovigilance payments, angling for a more "balanced and transparent" system. More

> Pfizer ($PFE) is resuming shipping of thyroid-disorder drug Levoxyl, which was in short supply after a manufacturing quality problem spurred a recall. Report (sub. req.)

> China's pharmaceutical industry saw steady growth in 2013, with revenues increasing 17.9% to about $355.4 billion. Story

> The FDA has approved Iroko's Tivorbex, a non-steroidal anti-inflammatory. Release

Medical Device News

@FierceMedDev: Boston Scientific is trying to nip at Medtronic's heels, as far as neuromodulation goes. Has it been successful? Report | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical may not be #1 in neuromodulation, but it is pushing hard to get there. Report | Follow @MarkHFierce

@MichaelGFierce: An FDA panel wants to change iontophoresis drug delivery regulation. More (reg. req) | Follow @MichaelGFierce

@EmilyWFierce: Practice Fusion is teaming up with medical device companies to provide "real-time" accounts of patient health. Article  | Follow @EmilyWFierce

> Volcano moves the bar a notch higher for 2014 as restructuring continues. Story

> MIT, Apple and others help shape Quanttus' wearable clinical monitoring tech. More

> India moves closer to approving key medical device legislation. News

Biotech News

@FierceBiotech: Sanofi grabs a discovery pact with gut expert Ardelyx in $198M deal. Story | Follow @FierceBiotech

@JohnCFierce: Have to wonder about these bullish peak sales forecasts on dulaglutide. Are patients ready to switch based on easier dosing? | Follow @JohnCFierce

@DamianFierce: InterMune trading up 150% premarket. Here's why. | Follow @DamianFierce

@EmilyMFierce: Global tuberculosis R&D takes hit with AstraZeneca site closure. News | Follow @EmilyMFierce

> Antibiotics player Achaogen sets terms on $65M IPO. More

> Merck scuttles a $700M-plus Ariad deal and hands back a once-vaunted cancer drug. Article

Pharma Manufacturing News

> The FDA catches another Indian drugmaker falsifying data. News

> Ranbaxy halts production at 2 plants to tackle its regulatory mess. Story

> The FDA has expanded its equivalency testing of generics. Article

> GSK vows to maintain soccer fields in new U.K. plant. Story

> Hamburg says FDA's focus on India reflects its place in the global supply chain. Story

> Pfizer and MIT are looking for more efficient biologics manufacturing. Brief

Biotech Research News

> Gene therapy regenerates damaged tissue in pigs after heart attack. Story

> Reprogrammed skin cells could provide a way to regenerate liver tissue. Article

> Global tuberculosis R&D takes hit with AstraZeneca site closure. News

> HPV-like vaccine guards against skin tumors in mice. Article

> DOD selects Bavarian Nordic to develop vaccine against biological threats. News

> Berg, Parkinson's Institute partner to find biomarkers. Brief

And Finally... The bosses beind GlaxoSmithKline's ($GSK) £350 million ($584 million) development in Ulverston, U.K., say they're dedicated to replacing the site's existing sports facilities; plans include a new sports hall, new soccer pitches and a bowling green. Story

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.